Equities

Shanghai MicuRx Pharmaceutical Co Ltd

688373:SHH

Shanghai MicuRx Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)3.90
  • Today's Change-1.49 / -27.64%
  • Shares traded2.21m
  • 1 Year change-47.01%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, cash reserves at Shanghai MicuRx Pharmaceutical Co Ltd fell by 13.61m. However, Cash Flow from Investing totalled 334.63m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 329.08m for operations while cash used for financing totalled 19.61m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.8664
Tangible book value per share0.8637
More ▼

Balance sheet in CNYView more

Shanghai MicuRx Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 34.88%, a higher figure than the previous year's 20.24%.
Current ratio6.79
Quick ratio6.43
Total debt/total equity0.5355
Total debt/total capital0.3488
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.